HighTower Advisors LLC raised its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 10.3% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 155,503 shares of the medical research company’s stock after purchasing an additional 14,572 shares during the period. HighTower Advisors LLC owned approximately 0.11% of Natera worth $64,271,000 as of its most recent SEC filing.
Other large investors also recently made changes to their positions in the company. Trust Co. of Vermont bought a new stake in shares of Natera during the second quarter valued at about $26,000. IFG Advisory LLC purchased a new stake in shares of Natera in the third quarter worth about $40,000. Elevation Wealth Partners LLC bought a new position in shares of Natera in the second quarter valued at approximately $30,000. Continuum Advisory LLC purchased a new position in Natera during the second quarter valued at approximately $33,000. Finally, Rakuten Securities Inc. purchased a new stake in Natera in the 2nd quarter worth approximately $35,000. 99.90% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on NTRA shares. BTIG Research raised their target price on shares of Natera from $320.00 to $430.00 and gave the company a “buy” rating in a research note on Tuesday, October 27th. Leerink Partners set a $330.00 price target on shares of Natera in a report on Friday, August 7th. Wells Fargo & Company lifted their price objective on shares of Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Rothschild & Co Redburn began coverage on shares of Natera in a research report on Tuesday, September 8th. They issued a “buy” rating and a $385.00 target price for the company. Finally, Morgan Stanley increased their target price on Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $394.31.
Get Our Latest Stock Report on Natera
Insider Transactions at Natera
In related news, CEO Steven Chapman sold 3,801 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the completion of the transaction, the chief executive officer directly owned 87,431 shares of the company’s stock, valued at approximately $36,004,085.80. This trade represents a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,419 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the sale, the insider directly owned 101,323 shares in the company, valued at approximately $41,519,125.71. The trade was a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 47,056 shares of company stock valued at $17,760,989 over the last three months. Corporate insiders own 5.05% of the company’s stock.
Natera Price Performance
Shares of NASDAQ:NTRA opened at $289.50 on Thursday. The stock’s 50-day simple moving average is $377.35 and its two-hundred day simple moving average is $272.44. Natera, Inc. has a 52-week low of $181.00 and a 52-week high of $437.41.
Natera (NASDAQ:NTRA – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.14). The business had revenue of $793.98 million for the quarter, compared to analysts’ expectations of $707.54 million. Natera had a negative net margin of 5.66% and a negative return on equity of 8.61%. Natera’s revenue for the quarter was up 34.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.64) EPS. Equities analysts anticipate that Natera, Inc. will post -1.25 earnings per share for the current year.
Natera Profile
Natera, Inc. is a diagnostics company that develops and provides genetic testing and molecular diagnostics for reproductive health, oncology and organ health. Its tests analyze cell-free DNA and other genetic material to support screening, diagnosis and disease monitoring. In reproductive health, Natera offers Panorama, a noninvasive prenatal screening test, and Horizon, a carrier screening test. Its oncology portfolio includes Signatera, a personalized circulating tumor DNA test used to monitor for molecular residual disease and assess cancer recurrence.
Featured Stories
- Five stocks we like better than Natera
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
